---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-002523"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T04:08:55.756328+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics appoints Dr. Michael B. Atkins, cancer immunotherapy expert, to board

## Summary
- Dr. Atkins appointed as Class III director effective Jan. 4, 2024; will serve until 2024 annual meeting.
- He brings over 30 years of translational and clinical research in melanoma, kidney cancer, and immunotherapy.
- Appointed to Nominating and Corporate Governance Committee.
- Receives annual cash compensation of $40,000 plus $4,000 committee fee; granted option for 35,000 shares at $5.25.
- Option vests one-third on first anniversary, then monthly over three years, subject to continued service.

## SEC filing metadata
- accession: 0001193125-24-002523
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000119312524002523/0001193125-24-002523-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000119312524002523/d705253d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-002523
- JSON: https://secwatch.observer/filing/0001193125-24-002523.json
- Plain text: https://secwatch.observer/filing/0001193125-24-002523.txt

## Key facts
- Executive change
  Michael B. Atkins was appointed as director at Werewolf Therapeutics, Inc..
  - Action: appointed
  - Role: director
  source text: On January 4, 2024, the Board of Directors (the “Board”) of Werewolf Therapeutics, Inc. (the “Company”), upon recommendation of the Board’s Nominating and Corporate Governance Committee, appointed Michael B. Atkins, M.D., as a director.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1785530/000119312524002523/0001193125-24-002523-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.